Abstract:In recent years, cell-based immunotherapies have demonstrated promising results in the treatment of cancer. Chimeric antigen receptors (CARs) arm effector cells with a weapon for targeting tumor antigens, licensing engineered cells to recognize and kill cancer cells. The quality of the CAR-antigen interaction strongly depends on the selected tumor antigen and its expression density on cancer cells. CD19 CAR-engineered T cells approved by the Food and Drug Administration have been most frequently applied in the treatment of hematological malignancies. Clinical challenges in their application primarily include cytokine release syndrome, neurological symptoms, severe inflammatory responses, and/or other off-target effects most likely mediated by cytotoxic T cells. As a consequence, there remains a significant medical need for more potent technology platforms leveraging cell-based approaches with enhanced safety profiles. A promising population that has been advanced is the natural killer (NK) cell, which can also be engineered with CARs. NK cells which belong to the innate arm of the immune system recognize and kill virally infected cells as well as (stressed) cancer cells in a major histocompatibility complex I independent manner. NK cells play an important role in the host's immune defense against cancer due to their specialized lytic mechanisms which include death receptor (i.e., Fas)/death receptor ligand (i.e., Fas ligand) and granzyme B/perforin-mediated apoptosis, and antibody-dependent cellular cytotoxicity, as well as their immunoregulatory potential via cytokine/chemokine release. To develop and implement a highly effective CAR NK cell-based therapy with low side effects, the following three principles which are specifically addressed in this review have to be considered: unique target selection, well-designed CAR, and optimized gene delivery.

A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Application and research progress of CAR-T cell therapy in autoimmune diseases

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer

Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy

CAR‐NK cell in cancer immunotherapy; A promising frontier

Application of CAR‐T Cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Advances and challenges in chimeric antigen receptor‐natural killer cell immunotherapy for cancer

Advances in CAR-NK cell therapy for hematological malignancies

Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects

CAR-NK cells: A promising cellular immunotherapy for cancer

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

CAR‐NK cells: the next wave of cellular therapy for cancer

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions